H
Humphrey Mulenga
Researcher at University of Cape Town
Publications - 44
Citations - 1270
Humphrey Mulenga is an academic researcher from University of Cape Town. The author has contributed to research in topics: Tuberculosis & Mycobacterium tuberculosis. The author has an hindex of 14, co-authored 36 publications receiving 846 citations. Previous affiliations of Humphrey Mulenga include TuBerculosis Vaccine Initiative & Stellenbosch University.
Papers
More filters
Journal ArticleDOI
Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination
Elisa Nemes,Hennie Geldenhuys,Virginie Rozot,Kathryn Tucker Rutkowski,Frances Ratangee,Nicole Bilek,Simbarashe Mabwe,Lebohang Makhethe,Mzwandile Erasmus,Asma Toefy,Humphrey Mulenga,Willem A. Hanekom,Steven G. Self,Linda-Gail Bekker,Ryall Robert P,Sanjay Gurunathan,Carlos A. DiazGranados,Peter Andersen,Ingrid Kromann,Thomas J. Evans,Ruth D. Ellis,Bernard Landry,David A. Hokey,Robert Hopkins,Ann M. Ginsberg,Thomas J. Scriba,Mark Hatherill +26 more
TL;DR: The rate of sustained QFT conversion, which may reflect sustained M. tuberculosis infection, was reduced by vaccination in a high‐transmission setting, and this finding may inform clinical development of new vaccine candidates.
Journal ArticleDOI
A Phase IIa Trial of the New Tuberculosis Vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis–infected Adults
Thomas J. Scriba,Michele Tameris,Erica Smit,Linda van der Merwe,E. Jane Hughes,Blessing Kadira,Katya Mauff,Sizulu Moyo,Nathaniel Brittain,Alison M. Lawrie,Humphrey Mulenga,Marwou de Kock,Lebohang Makhethe,Esme Janse van Rensburg,Sebastian Gelderbloem,Ashley Veldsman,Mark Hatherill,H. Geldenhuys,Adrian V. S. Hill,Anthony Hawkridge,Gregory D. Hussey,Willem A. Hanekom,Helen McShane,Hassan Mahomed +23 more
TL;DR: MVA85A was safe and immunogenic in persons with HIV and/or M.tb- and-or HIV-infected persons in a setting where TB and HIV are endemic and further evaluation of safety and efficacy of this vaccine for prevention of TB in these target populations is supported.
Journal ArticleDOI
Predictive Value of Recent QuantiFERON Conversion for Tuberculosis Disease in Adolescents
Shingai Machingaidze,Suzanne Verver,Humphrey Mulenga,Deborah-Ann Abrahams,Mark Hatherill,Willem A. Hanekom,Gregory D. Hussey,Hassan Mahomed +7 more
TL;DR: Recent QFT conversion was indicative of an approximately eight fold higher risk of progression to TB disease (compared with nonconverters) within 2 years of conversion in a cohort of adolescents in a high-TB burden population.
Journal ArticleDOI
Dose-Finding Study of the Novel Tuberculosis Vaccine, MVA85A, in Healthy BCG-Vaccinated Infants
Thomas J. Scriba,Michele Tameris,Nazma Mansoor,Erica Smit,Linda van der Merwe,Katya Mauff,E. Jane Hughes,Sizulu Moyo,Nathaniel Brittain,Alison M. Lawrie,Humphrey Mulenga,Marwou de Kock,Sebastian Gelderbloem,Ashley Veldsman,Mark Hatherill,H. Geldenhuys,Adrian V. S. Hill,Gregory D. Hussey,Hassan Mahomed,Willem A. Hanekom,Helen McShane +20 more
TL;DR: The safety of and characterized the T cell response induced by 3 doses of the candidate vaccine, MVA85A, in BCG-vaccinated infants from a setting where tuberculosis is endemic, and data support efficacy evaluation of MVA 85A to prevent tuberculosis in infancy.
Journal ArticleDOI
Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial.
Thomas J. Scriba,Andrew Fiore-Gartland,Adam Penn-Nicholson,Humphrey Mulenga,Stanley Kimbung Mbandi,Bhavesh Borate,Simon C Mendelsohn,Katie Hadley,Chris Hikuam,Masooda Kaskar,Munyaradzi Musvosvi,Nicole Bilek,Steven G. Self,Tom Sumner,Richard G. White,Mzwandile Erasmus,Lungisa Jaxa,Rodney Raphela,Craig Innes,William Brumskine,Andriëtte Hiemstra,Stephanus T. Malherbe,Razia Hassan-Moosa,Razia Hassan-Moosa,Michele Tameris,Gerhard Walzl,Kogieleum Naidoo,Kogieleum Naidoo,Gavin J. Churchyard,Mark Hatherill,Kesenogile Baepanye,Tshepiso Baepanye,Ken Clarke,Marelize Collignon,Audrey Dlamini,Candice Eyre,Tebogo Feni,Moogo Fikizolo,Phinda Galane,Thelma Goliath,Alia Gangat,Shirley Malefo-Grootboom,Elba Janse van Rensburg,Bonita Janse van Rensburg,Sophy Kekana,Marietjie Zietsman,Adrianne Kock,Israel Kunene,Aneessa Lakhi,Nondumiso Langa,Hilda Ledwaba,Marillyn Luphoko,Immaculate Mabasa,Dorah Mabe,Nkosinathi Mabuza,Molly Majola,Mantai Makhetha,Mpho Makoanyane,Blossom Makhubalo,Vernon Malay,Juanita Market,Selvy Matshego,Nontsikelelo Mbipa,Tsiamo Mmotsa,Sylvester Modipa,Samuel Mopati,Palesa Moswegu,Primrose Mothaga,Dorothy Muller,Grace Nchwe,Maryna Nel,Lindiwe Nhlangulela,Bantubonke Ntamo,Lawerence Ntoahae,Tedrius Ntshauba,Nomsa Sanyaka,Letlhogonolo Seabela,Pearl Selepe,Melissa Senne,MG Serake,Maria Thlapi,Vincent Tshikovhi,Lebogang Tswaile,Amanda van Aswegen,Lungile Mbata,Constance Takavamanya,Pedro Pinho,John Mdlulu,Marthinette Taljaard,Naydene Slabbert,Sharfuddin Sayed,Tanya Nielson,Ni Ni Sein,Dhineshree Govender,Tilagavathy Chinappa,Mbali Ignatia Zulu,Nonhle Bridgette Maphanga,Senzo Ralph Hlathi,Goodness Khanyisile Gumede,Thandiwe Yvonne Shezi,Jabulisiwe Lethabo Maphanga,Zandile Patrica Jali,Thobelani Cwele,Nonhlanhla Zanele Elsie Gwamanda,Celaphiwe Dlamini,Zibuyile Phindile Penlee Sing,Ntombozuko Gloria Ntanjana,Sphelele Simo Nzimande,Siyabonga Mbatha,Bhavna Maharaj,Atika Moosa,Cara-Mia Corris,Fazlin Kafaar,Hennie Geldenhuys,Angelique Kany Kany Luabeya,Justin Shenje,Natasja Botes,Susan Rossouw,Hadn Africa,Bongani Diamond,Samentra Braaf,Sonia Stryers,Alida Carstens,Ruwiyda Jansen,Simbarashe Mabwe,Roxane Herling,Ashley Veldsman,Lebohgang Makhete,Marcia Steyn,Sivuyile Buhlungu,Margareth Erasmus,Ilse Davids,Patiswa Plaatjie,Alessandro Companie,Frances Ratangee,Helen Veldtsman,Christel Petersen,Charmaine Abrahams,Miriam Moses,Xoliswa Kelepu,Yolande Gregg,Liticia Swanepoel,Nomsitho Magawu,Nompumelelo Cetywayo,Lauren Mactavie,Habibullah Valley,Elizabeth Filander,Nambitha Nqakala,Elizna Maasdorp,Justine Khoury,Belinda Kriel,Bronwyn Smith,Liesel Muller,Susanne Tonsing,Andre G. Loxton,Petri Ahlers,Marika Flinn,Eva Chung,Michelle Chung,Alicia Sato +159 more
TL;DR: In this article, the authors tested performance of a transcriptomic signature of tuberculosis (RISK11) and efficacy of signature-guided preventive therapy in parallel, using a hybrid three-group study design.